Akari Therapeutics, Plc (AKTX)

$0.5

-0.03 (-5.32%)
Rating:
Recommendation:
Buy
Symbol AKTX
Price $0.5
Beta 1.436
Volume Avg. 0.08M
Market Cap 37.225M
Shares () -
52 Week Range 0.38-1.61
1y Target Est -
DCF Unlevered AKTX DCF ->
DCF Levered AKTX LDCF ->
ROE -184.77% Strong Sell
ROA -159.14% Strong Sell
Operating Margin -
Debt / Equity 36.58% Neutral
P/E -
P/B 3.56 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AKTX news


Dr. David Solomon
Healthcare
Biotechnology
NASDAQ Capital Market

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.